1. Home
  2. GCDT vs APVO Comparison

GCDT vs APVO Comparison

Compare GCDT & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCDT

Green Circle Decarbonize Technology Limited Ordinary Shares

N/A

Current Price

$0.67

Market Cap

9.9M

Sector

Industrials

ML Signal

N/A

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.87

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCDT
APVO
Founded
1992
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
GCDT
APVO
Price
$0.67
$4.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1M
26.2K
Earning Date
05-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.50
52 Week High
$5.32
$10.70

Technical Indicators

Market Signals
Indicator
GCDT
APVO
Relative Strength Index (RSI) 44.37 46.19
Support Level $0.65 $4.29
Resistance Level $1.47 $5.59
Average True Range (ATR) 0.20 0.28
MACD 0.00 -0.02
Stochastic Oscillator 12.69 19.70

Price Performance

Historical Comparison
GCDT
APVO

About GCDT Green Circle Decarbonize Technology Limited Ordinary Shares

Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: